GALDERMA GROUP AG (GALDY) Key Metrics
GALDY valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $49.52B
- Enterprise value
- $47.58B
- P/E (TTM)
- 58.2
- Forward P/E
- 29.9
- PEG ratio
- 1.17
- Price / sales
- 8.4
- Price / book
- 5.5
- EV / EBITDA
- 33.4
- Dividend yield
- 0.21% $0.09 a year
- Beta
- −0.05
GALDY key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGALDY valuation Price multiples at each fiscal year-end price.
GALDY returns How much profit the business earns on the capital it uses.
GALDY per-share figures Results divided by the shares outstanding at year-end.
GALDY financial health Debt, liquidity and how easily interest is covered.
GALDY efficiency & capital use Working capital cycle and where the cash goes.
GALDY valuation history
GALDY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GALDY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GALDY cash returned to shareholders
GALDY price vs earnings per share
GALDY key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $9.72B | $5.33B | — |
| Enterprise value | $11.52B | $7.51B | — |
| P/E ratio | 15.9 | 23.1 | — |
| Price / sales | 1.9 | 1.2 | — |
| Price / book | 1.2 | 0.7 | — |
| Price / free cash flow | 9.4 | 25.0 | — |
| Price / operating cash flow | 8.2 | 10.9 | — |
| EV / sales | 2.2 | 1.7 | — |
| EV / EBITDA | 10.1 | 7.8 | — |
| EV / free cash flow | 11.2 | 35.3 | — |
| Earnings yield | 6.3% | 4.3% | — |
| Free cash flow yield | 10.6% | 4.0% | — |
| Dividend yield | 0.4% | — | — |
| Shareholder yield (dividends + buybacks) | 4.2% | 0.3% | — |
| Share price at fiscal year-end | $41.45 | $22.45 | — |
| Per share | |||
| Revenue per share | $22.34 | $18.70 | $17.33 |
| Earnings per share | $2.61 | $0.97 | −$0.24 |
| Operating cash flow per share | $5.05 | $2.06 | $0.69 |
| Free cash flow per share | $4.40 | $0.90 | $0.05 |
| Cash per share | $3.33 | $1.92 | $1.55 |
| Book value per share | $34.74 | $32.81 | $22.60 |
| Tangible book value per share | −$6.90 | −$9.13 | −$19.71 |
| Dividends per share | $0.17 | — | — |
| Capex per share | $0.66 | $1.16 | $0.64 |
| Debt per share | $10.99 | $11.11 | $19.99 |
| Shares outstanding | 234.6M | 237.4M | 237.6M |
| Change in shares outstanding | −1.2% | −0.1% | — |
| Returns & profitability | |||
| Return on equity (ROE) | 7.7% | 3.5% | −1.1% |
| Return on invested capital (ROIC) | 6.9% | 5.4% | 5.0% |
| Return on assets (ROA) | 4.7% | 1.8% | −0.5% |
| Return on tangible assets | 16.9% | 8.7% | −2.4% |
| Free cash flow margin | 19.7% | 4.8% | 0.3% |
| Income quality (OCF / net income) | 1.93 | 2.11 | — |
| Financial health | |||
| Total debt | $2.58B | $2.64B | $4.75B |
| Cash & short-term investments | $780.0M | $457.0M | $368.0M |
| Net debt | $1.80B | $2.18B | $4.38B |
| Debt / equity | 0.32 | 0.34 | 0.88 |
| Debt / assets | 0.19 | 0.21 | 0.38 |
| Net debt / EBITDA | 1.58 | 2.27 | 5.15 |
| Current ratio | 1.19 | 1.21 | 1.03 |
| Quick ratio | 0.93 | 0.94 | 0.76 |
| Interest coverage | 5.0 | 1.9 | 1.1 |
| Working capital | $382.0M | $315.0M | $45.0M |
| Invested capital | $9.95B | $9.97B | $9.75B |
| Tangible asset value | −$1.62B | −$2.17B | −$4.68B |
| Net current asset value | −$2.81B | −$2.98B | −$5.49B |
| Graham number | $45.20 | $26.80 | — |
| Graham net-net per share | −$15.06 | −$15.18 | −$25.47 |
| Capital allocation | |||
| Dividends paid | $41.0M | — | — |
| Share buybacks (net) | $363.0M | $15.0M | $0 |
| Dividend payout ratio | 6.7% | — | — |
| Dividends + buybacks / free cash flow | 39.2% | 7.0% | 0.0% |
| Capex / revenue | 2.9% | 6.2% | 3.7% |
| Capex / operating cash flow | 13.0% | 56.4% | 92.7% |
| Capex / depreciation | 0.48 | 0.94 | 0.55 |
| Stock-based compensation / revenue | 1.2% | 1.5% | 0.0% |
| R&D / revenue | 4.7% | 5.9% | 7.0% |
| SG&A / revenue | 45.3% | 46.2% | 46.0% |
| Efficiency | |||
| Days sales outstanding | 57.4 | 56.9 | 55.9 |
| Days of inventory on hand | 103.8 | 110.8 | 124.4 |
| Days payables outstanding | 153.3 | 151.9 | 165.0 |
| Cash conversion cycle (days) | 7.8 | 15.8 | 15.4 |
| Receivables turnover | 6.36 | 6.41 | 6.52 |
| Payables turnover | 2.38 | 2.40 | 2.21 |
| Inventory turnover | 3.52 | 3.29 | 2.93 |
| Asset turnover | 0.40 | 0.35 | 0.33 |
| Average receivables | $823.5M | $692.5M | $631.0M |
| Average payables | $685.5M | $564.0M | $557.0M |
| Average inventory | $464.0M | $411.5M | $420.0M |
| Intangibles / total assets | 72.9% | 78.9% | 80.6% |
Computed from GALDY's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GALDY valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), GALDERMA GROUP traded at 15.9 times earnings. Based on the latest twelve months, the trailing P/E is 58.2 and the forward P/E is 29.9. GALDERMA GROUP earned a return on equity of 7.7% and a return on invested capital of 6.9% in fiscal 2025. It ended the year with $2.6 billion of debt and $780.0 million in cash and short-term investments, net debt of $1.8 billion. It returned $404.0 million to shareholders: $41.0 million in dividends and $363.0 million in share buybacks, 39% of free cash flow.
See the GALDY income statement, the GALDY chart for price history, or the GALDY stock overview for the latest quote and news.
GALDY key metrics FAQ
What is GALDERMA GROUP's P/E ratio?
GALDERMA GROUP's trailing P/E ratio is 58.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 29.9. At the end of fiscal 2025 it was 15.9.
What is GALDERMA GROUP's EV/EBITDA?
GALDERMA GROUP's enterprise value was 10.1 times EBITDA at the end of fiscal 2025 (enterprise value $11.5 billion, EBITDA $1.1 billion); the current EV/EBITDA is 33.4.
What is GALDERMA GROUP's return on equity?
GALDERMA GROUP's return on equity (ROE) was 7.7% in fiscal 2025: net income of $613.0 million on average shareholders' equity of $8.0 billion.
What is GALDERMA GROUP's ROIC?
GALDERMA GROUP's return on invested capital was 6.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does GALDERMA GROUP have?
GALDERMA GROUP had total debt of $2.6 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.32 and $1.8 billion of net debt (1.58 times EBITDA).
What is GALDERMA GROUP's dividend yield?
GALDERMA GROUP's forward dividend yield is 0.21%. GALDERMA GROUP paid $41.0 million in dividends in fiscal 2025 ($0.17 per share), a payout ratio of 6.7%.
Does GALDERMA GROUP buy back its shares?
Yes. GALDERMA GROUP spent $363.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −1.2% over the year, to 234.6M..
What is GALDERMA GROUP's free cash flow yield?
GALDERMA GROUP generated $1.0 billion of free cash flow in fiscal 2025, a free cash flow yield of 10.6% on its market value at year-end ($9.7 billion).
What is GALDERMA GROUP's current ratio?
GALDERMA GROUP's current ratio was 1.19 at the end of fiscal 2025: current assets were 1.19 times current liabilities.